News

Johnson & Johnson Innovation Grant Aimed at Veteran Healthcare

A 2021 report by the U.S. Department of Health and Human Services found that Veterans are significantly more likely to develop multiple chronic health conditions in their lifetime like hypertension, arthritis, and cancer compared to non-Veterans. [1] To help treat wounded warriors and keep the military community healthy, we feel we must seek to identify and advance solutions with the potential to help address their medical needs.

To that end, Johnson & Johnson Innovation, together with Johnson & Johnson Office of Military and Veterans Affairs, is proud to continue the Veterans Lead QuickFire Challenge series. Innovators are invited to submit potentially ground-breaking ideas that aim to directly address the health care needs of the military community including cardiovascular disease [2], kidney disease [3], oncology [4], orthopedic and musculoskeletal disease [5], physical trauma management [6], respiratory health [7], and vision loss. [8]

The innovator(s) with the best idea, technology, or potential solution can receive grant funding from up to a total of $250,000, access to the Johnson & Johnson Innovation – JLABS ecosystem, and mentorship from experts across the Johnson & Johnson Family of Companies*.

* Subject to the execution of the necessary documentation and award agreement

 

Application Process

Potential solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Uniqueness of the idea
  • Potential impact on human health, specifically the military-connected community’s health
  • Feasibility of the idea
  • Thoroughness of approach
  • Identification of key resources and plan to further idea

The challenge is now accepting applications. The deadline to apply is September, 17 2021.

Recent News

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin

07/07/2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the